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In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present 
complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major 
cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating 
agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, 
deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These 
practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), 
presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and 
the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with 
evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron 
chelation protocol for patients with thalassemia under regular transfusions.
Keywords: Blood transfusion; Chelation therapy; Deferiprone; Deferasirox; Iron/metabolism; beta-Thalassemia; 
Iron overload; Iron chelating agents; Magnetic resonance imaging; Practice guidelines as topic; Protocols; Brazil
Introduction
Transfusion-dependent patients with thalassemia major (TM) develop iron overload 
which leads to damage of the liver, heart, and endocrine organs and related morbidity and 
mortality(1,2). Improvements in survival have been achieved over the last 40 years due to iron 
chelation therapy and iron assessment by serum ferritin, and liver/cardiac magnetic resonance 
imaging (MRI) techniques(3).
The need to have an iron chelation protocol in Brazil to guide the treatment led to the 
development of this guideline.
Iron chelation therapy
Iron chelation therapy with desferrioxamine (DFO), available since the late 1960s and the 
most widely used iron chelator, decreased iron overload-related complications and mortality rate of 
patients with TM(4-6). However, the long-term survival rate remained low and 50% of patients did not 
reach 35 years of age(7). Although available in many countries, one third of the patients developed 
signs of iron overload, such as delayed or absent puberty, growth disorders, hypothyroidism, 
hypogonadism, bone abnormalities, cirrhosis and heart disease (main cause of death in transfusion-
dependent patients with TM). These complications are related to a poor compliance to treatment, 
due to the subcutaneous administration (SC) of DFO over at least 12 hours, 5-6 days per week(1,2). 
However, some patients with good compliance to DFO still develop these problems(2,8).
Deferiprone (DFP), an oral iron chelator, has been available for use in Europe and other 
countries since 1999. Several studies showed that DFP (75 mg/kg/day) leads to a negative 
iron balance in patients with TM and reduces the iron measured by ferritin level or liver iron 
concentration (LIC)(9,10).
Higher doses of DFP (100 mg/kg/day) or combination therapy with DFO make the treatment 
more effective in reducing iron overload(10-18). DFP plays an important role in protecting the 
heart(14,16,18,19). In an eight-year follow up, no cardiac event was found in patients with TM receiving 
DFP, while ten deaths were recorded related to heart failure in patients treated with DFO(20). A 
randomized controlled trial in patients with cardiac T2* MRI values from 8-20 ms and normal 
cardiac function showed that DFP monotherapy was superior to DFO in improving the cardiac 
T2* MRI and cardiac function(21). DFP combined with SC DFO led to lower serum ferritin levels, 
suggesting an additive or synergic effect between the two chelators(11-18). Combination therapy can 
slowly improve the cardiac dysfunction in patients with severe iron overload and asymptomatic 
or symptomatic heart disease(22,23). Continuous intravenous DFO is slower than combined therapy 
in reducing cardiac iron and the adverse events related to the catheter device make such therapy 
difficult. However, continuous DFO can be used when DFP is contraindicated(24,25).
Deferasirox (DFX), an oral iron chelator, is approved worldwide for over two-year-old 
patients with the advantage of being administered once a day because its plasma half-life 
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is 11-19 hours, thus it offers 24-hour protection against labile 
plasma iron and reduces tissue injuries(25). A phase III prospective 
randomized clinical trial, comparing DFO and DFX, brought 
new alternatives to the treatment of patients with transfusion-
related iron overload. DFX (20-30 mg/kg/day) proved to be as 
effective as DFO (40-50 mg/kg/day) in inducing a negative iron 
balance as measured by ferritin level and LIC(26). DFX safety and 
efficacy were confirmed over time(27,28). DFX can remove cardiac 
iron(29-32). The Evaluation of Patients’ Iron Chelation with Exjade 
(EPIC) trial(30-32) demonstrated, in a prospective, multicenter 
trial with 192 patients randomized in two arms, that DFX can 
prevent or remove cardiac iron. The improvement in myocardial 
T2* MRI in patients with cardiac iron overload was associated 
with maintained left ventricular ejection fraction (LVEF), while 
in patients without cardiac iron overload (prevention arm), LVEF 
improved significantly. The DFX optimal dose for cardiac iron 
chelation is 30-40 mg/kg/day.
Patients with TM can have iron overload in the liver and not 
in the heart(33). Younger patients usually have detectable cardiac 
iron overload after the age of 9.5 years(34,35). However, patients with 
suboptimal chelation therapy can develop cardiac iron overload 
earlier, suggesting a need for MRI screening at 7 years of age if 
poor chelation is assumed, even in the absence of heart disease 
symptoms(36). An individual assessment of iron overload is important 
for the appropriate chelation therapy(33). The chelation therapy must 
reduce the free iron and, as a consequence, reduce cellular damage.
Iron overload assessment
1. Serum ferritin and transferrin saturation
Serum ferritin is an indirect measure of body iron and is useful to 
monitor iron chelation over time. Ferritin is also an acute-phase serum 
protein, so it can be naturally high during acute or chronic inflammation 
and infections; or decreased in ascorbate deficiency(37). There is a 
correlation between serum ferritin and LIC(38). Ferritin levels ≤ 2.500 
ng/mL are significantly correlated to higher cardiac disease-free 
survival rates(1,5,6). Some patients may develop cardiac iron overload 
even with low serum ferritin because there is lack of a clinically useful 
correlation between serum ferritin and cardiac iron overload measured 
by MRI in patients with TM on regular transfusions(8), justifying the 
need to monitor iron overload with both tests.
Frequent blood transfusions cause a gradual increase 
in transferrin saturation, which leads to the presence of non-
transferrin-bound iron (NTBI) in the plasma(39). The toxic 
component is called labile plasma iron (LPI) and is prevalent 
when transferrin saturation is > 70%.
2. Liver iron concentration
Liver iron can predict a clinical outcome, as patients with less 
LIC survive longer(4) and have more cardiac disease-free survival(5). 
LIC can be measured by biopsy, superconducting quantum 
interference device (SQUID) and MRI (R2/R2*). As MRI R2/R2* is 
a non-invasive procedure compared to liver biopsy and shows good 
correlation with liver iron, this exam should be used to measure 
LIC(40). If LIC is severe, the MRI should be repeated in 6 months.
3. Myocardial iron concentration
Cardiac function must be assessed by echocardiogram(41). 
Decreased LVEF or increased end-systolic volume are related to 
potential cardiac iron overload, increasing the risk of developing 
heart disease(42). These changes must be detected early because 
they are associated with a high mortality rate(1,22). Cardiac MRI, 
using the relaxation time T2* measured in the heart interventricular 
septum, is a technique that is reproducible and accurate(33,43,44) and 
has improved the knowledge on cardiac disease in transfusion-
dependent patients(3,33-36). Low myocardial T2* predicts a high risk 
of developing heart failure and arrhythmia. Heart failure occurred 
in 47% of patients within one year of a cardiac T2* values < 6 ms 
with a relative risk of 270 (95% confidence interval: 64-1129). All 
patients with reduced LVEF had cardiac iron overload and only 0.2% 
of them developed heart failure with T2* values > 10 ms(3).
4. Iron assessment
Proper management requires access to cardiac MRI. If the 
first MRI shows a T2* > 20 ms, the exam should be repeated in 
one year. If T2* < 20 ms, the MRI should be performed annually 
or more frequently according to chelation therapy and the severity 
of cardiac iron overload. By using T2* MRI, it is possible, in 
the same procedure, to determine the degree of iron overload of 
different organs besides the heart, such as the liver, pituitary gland 
and pancreas as well as gain information on cardiac volumes and 
function. LIC(45) and myocardial iron concentration (MIC)(46) values 
are calculated according to previously published data that correlate 
MRI values to directly measured iron by biopsy (Table 1):
Table 1: Correlation between iron overload detected by magnetic resonance 
imaging (ms) and tissue (mg Fe/g dry weight)
Liver(45) Normal Mild Moderate Severe
T2* (ms) > 11.4 3.8 - 11.4 1.8-3.8 < 1.8
R2* (Hz) < 88 88-263 263-555 > 555
LIC (mg Fe/g dry wet) < 2 2-7 7-15 > 15
Cardiac(46) Normal Mild Moderate Severe
T2* (ms) > 20 15-20 10-15 < 10
R2* (Hz) < 50 50-66.5 66.6-100 > 100
MIC (mg Fe/g dry wet) < 1.16 1.16 - 1.65 1.65 - 2.71 > 2.71
LIC: liver iron concentration; MIC: myocardial iron concentration
Iron chelators: characteristics
The characteristics of iron chelators are listed in Table 
2. The dose must be reduced if ferritin levels are consistently 
< 500 ng/mL(47,48) unless there is evidence or iron overload by 
T2* MRI. Anticontraceptive methods should be used by fertile 
age female patients.
DFO dose must be adjusted according to ferritin levels when 
started in under three-year-old children; it is important to use 
reduced doses and monitor bone growth. Yersinia and Klebsiella 
infections can be fatal if not recognized and treated early. DFO 
should be discontinued in the presence of fever, until there is no 
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Table 2: Main characteristics of iron chelators
Desferrioxamine(41) Deferiprone(9,10,12,16,17,49,50) Deferasirox(26,28,31,32)
Indications Thalassemia major or intermedia on regular blood transfusions (> 10 transfusions)Ferritin levels > 1000 ng/mL
Age All > 6 years > 2 years
Adverse events Skin - local reactions;
Hearing loss to high frequencies;
Visual disturbances;
Allergy;
Growth failure;
Osteoporosis;
Yersinia and Klebsiella infections;
Pneumonitis or renal failure due to high doses or fast infusion 
rates (rare)
Neutropenia;
Agranulocytosis (0.6/100 
patients/year);
Thrombocytopenia;
Gastrointestinal 
disturbances;
Increased liver enzymes;
Arthropathy
Skin rash;
Gastrointestinal 
disturbances;
Mild non-progressive 
increases in serum 
creatinine;
Increased liver enzymes
Monitoring
Weekly Neutrophil count
Monthly
Ferritin
Transaminases
Serum creatinine
Proteinuria
Every 3 months FerritinTransaminases 
Ferritin and transaminases 
(monthly in the first three 
months);
Clinical signs of zinc 
deficiency
Every 6 months Height and sitting height (Harpender Stadiometer)
Annually
Audiometric and ophthalmologic exams; Bone densitometry 
(begin at 10 years);
X-ray of long bones and spine
Audiometric and 
ophthalmologic exams; 
Growth in children
Contraindications
Discontinue therapy before pregnancy and resume after delivery; 
If the woman presents severe iron overload or cardiac failure, 
therapy can be resumed in the third trimester of pregnancy;
Allergy;
Bone lesions that may impair growth
Previous neutropenia 
and/or agranulocytosis 
(excluding 
hypersplenism);
Concomitant medication 
that causes neutropenia or 
agranulocytosis;
Pregnancy or breast-
feeding
Pregnancy or breast-
feeding
more risk of infection by these agents(41). Good compliance to 
DFO is considered when > 250 infusions/year are administered 
(five infusions/week)(6) and/or the compliance index is > 0.60(41).
Compliance
index
= Number of days of treatment/year
Number of days prescribed in the dosing schedule
DFP can be started when the absolute neutrophil count (ANC) 
> 1500/mm3 and platelets > 100,000/mm3; it must be temporary 
discontinued when ANC is 500-1500/mm³ and resumed when 
ANC is > 1500/mm³. An adverse event such as ANC < 500/mm3 
is a contraindication for the use of DFP. Patients with repeatedly 
low ANC should be investigated for infections such as  human 
erythrovirus (parvovirus) B19, cytomegalovirus (CMV) or Epstein–
Barr virus (EBV). If agranulocytosis persists for more than 72 hours 
or is associated with severe infection, granulocyte stimulating factor 
may be required(17,49). Early treatment of infections is recommended. 
In splenectomized patients, the ANC is calculated considering 
the white cell count minus erythroblasts, and counting only 
neutrophils(10,16,25,50). When necessary, replace zinc sulfate 200 mg 
two times per week(16).
DFX dose adjustment is done every three months based 
on ferritin. If serum creatinine has a non-progressive increase > 
33% over baseline value for adult patients or above the maximum 
value for the age for pediatric patients in two consecutive 
measurements and cannot be attributed to other causes, the dose 
must be reduced to 10 mg/kg/day. If there is a progressive increase 
in serum creatinine beyond the upper limit of the normal range, 
DFX should be discontinued. Therapy may be resumed according 
to individual circumstances. Intermittent proteinuria does not 
need discontinuation, but monthly control is recommended. 
Abdominal pain, nausea, vomiting or diarrhea can be controlled 
taking deferasirox in the evening. For mild-to-moderate skin rash, 
deferasirox may be continued without dose adjustment. For severe 
rash, where interruption of treatment may be necessary, deferasirox 
can be resumed after resolution of the rash at a lower dose followed 
by gradual dose escalation. For persistent and progressive increase 
in serum transaminase that cannot be attributed to other causes, 
deferasirox should be interrupted. After resolution, DFX can be 
resumed at a lower dose followed by gradual dose escalation.
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Chelator dose adjustment is done based on transfusional 
iron intake and ferritin levels measured each three months.
1. Patients naïve to iron chelation 
The serum ferritin must be assessed after ten blood 
transfusions and when ferritin > 1000 ng/mL in two measures 
within 60 days, or if the transferrin saturation is > 70-80% (free 
iron in the plasma)(54-56), the recommendation is to follow Figure 
1. Monitor DFO and DFX toxicity.
2. Patients with cardiac T2* value > 20 ms
Chelation therapy is based on cardiac and hepatic T2* 
values as shown in Figure 2. The liver iron clearance takes at 
least 12 months. Monitor DFO, DFP or DFX toxicity. Liver and 
cardiac MRI should be repeated every 12 months.
3. Patients with cardiac T2* value < 20 ms
Chelation therapy is based on cardiac and hepatic T2* 
values as shown in Figure 3. The liver iron clearance takes at least 
12 months and cardiac iron clearance takes even longer. Monitor 
Protocol
Based on the medical literature, the Scientific Committee 
of the Brazilian Association of Thalassemia (ABRASTA) is 
suggesting an iron chelation therapy protocol for transfusional 
iron overload and thalassemia. The objective is to help 
hematologists to choose the most appropriate chelation therapy 
for their patients. The trials were carefully selected and they 
provide consistent evidence on strategies to be adopted for 
patients with iron overload.
The classification criteria for the recommendations (grades A, 
B, C and D) listed in this protocol are similar to those adopted by the 
‘Projeto Diretrizes’, guidelines developed by the Associação Médica 
Brasileira (AMB) and the Conselho Federal de Medicina (CFM)(51).
These guidelines are based on changes in the MIC and LIC 
measured by the T2* MRI method, LVEF and serum ferritin. We 
are proposing four situations: naïve iron chelation, cardiac T2* 
value > 20 ms, cardiac T2* value < 20 ms and MRI not available. 
If the patient is hepatitis C virus (HCV)-RNA-positive, iron 
chelation must be intensified in order to reduce LIC to decrease the 
potential for liver fibrosis and allow response to antiviral therapy 
(A)(52),(B)(53). Antiviral therapy administered concomitantly with 
DFP needs careful control.
Figure 1 - Iron chelation therapy for patients with thalassemia naïve to iron chelation
Figure 2 - Iron chelation therapy for patients with thalassemia without cardiac iron overload
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DFO, DFP or DFX toxicity, mainly with higher doses.
When cardiac T2* value < 20 ms, liver and cardiac MRI 
should be repeated in 12 months and echocardiogram (ECO), 
electrocardiogram (ECG) and Holter every 6-12 months. If the LVEF 
is normal, no medication is needed to improve cardiac function.
When cardiac T2* value < 10 ms and LVEF is normal, 
perform ECO, ECG, Holter and cardiac MRI each six months. If 
cardiac T2* remains the same or decreased after 6-12 months, with 
worsening LVEF, change chelation as if cardiac T2* value < 10 ms.
When cardiac T2* value < 10 ms and/or LVEF < 56%, 
ECO and ECG should be repeated in two months, then every six 
months, Holter and cardiac MRI every six months. If cardiac T2* 
is lower after six months or LVEF is worsening, repeat continuous 
administration of intravenous DFO and oral DFP.
4. Magnetic resonance imaging not available
The recommendations when the MRI is not available 
(unable to travel to the T2* MRI center, claustrophobia, metallic 
implants, unable to cooperate with the procedure), are shown in 
Figure 4. Cardiac disease is not common in under 18-year-old 
patients regularly taking DFO and with a mean ferritin level < 
2500 ng/mL. ECO, ECG and holter should be performed early 
to identify signs of left ventricular dysfunction or arrhythmias 
suggesting heart disease.
Combination therapy with DFP and DFX in patients 
with high iron overload or evidence of cardiac disease is still 
experimental(56).
Figure 3 - Iron chelation therapy for patients with thalassemia with cardiac iron overload
Figure 4 - Iron chelation therapy for patients with thalassemia when magnetic resonance imaging is not available
433
Brazilian Association of Thalassemia protocol for iron chelation therapy in patients under regular transfusion
Rev Bras Hematol Hemoter. 2013;35(6):428-34
General guidelines
1. When combination therapy cannot be implemented, use 
oral monotherapy with DFX at 40 mg/kg/day or DFP at 100 
mg/kg/day, but monitor carefully (A)(21,30)(B)(20,31).
2. When cardiac function returns to normal and cardiac T2* 
value > 20 ms, the patient can be treated as shown in Figure 2.
3. The response to antiviral therapy against HCV is better 
with low levels of LIC (A)(52)(B)(53).
Conclusion
The decision to prescribe an iron chelator must consider the 
indications and contraindications of each drug and the need to 
tailor therapy for each patient. These guidelines were designed 
to help hematologists in their decisions. However, it is essential 
to use their clinical judgment and to consider their patient’s 
individual needs when deciding on the recommendations.
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